Skip to main content
About Us
Image Credits
Contributor Info
RSS
Log In
Join
Twitter
E-Alerts
Visit StemJournal
Main menu
About
Image Credits
Contributor Info
E-Alerts
Chapters
Cellular and nuclear reprogramming
Ectoderm specification and differentiation
Endoderm specification and differentiation
Epigenetics
Genomics and proteomics
Germ cell and somatic stem cell biology in reproduction
Manufacturing
Mesoderm specification and differentiation
Niche biology, homing, and migration
Renewal
Stem cell immunology
Therapeutic prospects
Tissue engineering
Protocols
Ectoderm differentiation
Endoderm differentiation
Genome editing
Mesoderm differentiation
Pluripotent stem cells
PSC characterization
PSC genetic stability
Reprogramming
StemLabs
Stem Cell COREdinates
Core Facility Profiles
Boston Children's Hospital Human Neuron Core
Boston University Center for Regenerative Medicine iPSC Core
Columbia Stem Cell Initiative Stem Cell Core Facility
Harvard Stem Cell Institute iPS Core Facility
Stem Cell Protocols
Stem Cell Reagents
Other Resources
News & Profiles
Latest News
Stem Cell Institute Profiles
Journal Stream
Forum
Search form
Search
You are here
Home
Biblio
Author
Title
Type
[
Year
]
Filters:
Author
is
Palumbo, Antonio
[Clear All Filters]
2016
Palumbo A
,
Chanan-Khan A
,
Weisel K
,
Nooka AK
,
Masszi T
,
Beksac M
,
Spicka I
,
Hungria V
,
Munder M
,
Mateos MV
, et al.
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
N Engl J Med. 2016;375(8):754-766.
PubMed
Google Scholar
Bruno B
,
Auner HW
,
Gahrton G
,
Garderet L
,
Festuccia M
,
Ladetto M
,
Lemoli RM
,
Massaia M
,
Morris C
,
Palumbo A
, et al.
Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting).
Leuk Lymphoma. 2016:1-13.
PubMed
Google Scholar
2015
Dimopoulos MA
,
Moreau P
,
Palumbo A
,
Joshua D
,
Pour L
,
Hajek R
,
Facon T
,
Ludwig H
,
Oriol A
,
Goldschmidt H
, et al.
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Lancet Oncol. 2015.
PubMed
Google Scholar
Gay F
,
Cavallo F
,
Palumbo A
.
The Role of Pre-Transplant Induction Regimens and Autologous Stem Cell Transplantation in the Era of Novel Targeted Agents.
Drugs. 2015.
PubMed
Google Scholar
2014
Palumbo A
,
Cavallo F
,
Gay F
,
Di Raimondo F
,
Ben Yehuda D
,
Petrucci MTeresa
,
Pezzatti S
,
Caravita T
,
Cerrato C
,
Ribakovsky E
, et al.
Autologous Transplantation and Maintenance Therapy in Multiple Myeloma.
N Engl J Med. 2014;371(10):895-905.
PubMed
Google Scholar
Bringhen S
,
Petrucci MTeresa
,
Larocca A
,
Conticello C
,
Rossi D
,
Magarotto V
,
Musto P
,
Boccadifuoco L
,
Offidani M
,
Omedé P
, et al.
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study.
Blood. 2014.
PubMed
Google Scholar
Sonneveld P
,
Asselbergs E
,
Zweegman S
,
van der Holt B
,
Kersten MJosé
,
Vellenga E
,
van Marwijk-Kooy M
,
Broyl A
,
de Weerdt O
,
Lonergan S
, et al.
Phase 2 study of carfilzomib, thalidomide and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma.
Blood. 2014.
PubMed
Google Scholar